Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer

被引：0
|
作者：
Toffart, A. -C. [1 ,2 ]
Sakhri, L. [1 ,2 ]
Moro-Sibilot, D. [1 ,2 ]
机构：
[1] Ctr Hosp Univ A Michallon, UM Oncol Thorac, F-38043 Grenoble 9, France
[2] Univ Grenoble 1, Inst A Bonniot, INSERM, U823, Grenoble, France
来源：
REVUE DE PNEUMOLOGIE CLINIQUE | 2013年 / 69卷 / 02期
关键词：
EML4-ALK; Lung cancer; Crizotinib; Targeted therapy; Never smoker; Adenocarcinoma; EML4-ALK FUSION GENE; KINASE INHIBITOR; RESISTANCE; REARRANGEMENT; MUTATIONS; EFFICACY; MET; NPM;
D O I：
10.1016/j.pneumo.2012.11.010
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：111 / 116
页数：6
相关论文
共 50 条
  • [41] CRIZOTINIB VERSUS PEMETREXED OR DOCETAXEL CHEMOTHERAPY IN ADVANCED, ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A RANDOMIZED PHASE III STUDY (PROFILE 1007)
    Kim, Dong-wan
    Janne, Pasi A.
    Nakagawa, Kazuhiko
    Seto, Takashi
    Crino, I.
    Ahn, Myung-ju
    De Pas, T. M.
    Besse, Benjamin
    Solomon, Ben
    Blackball, Fiona
    Wu, Yi-long
    Thomas, Michael
    O'Byrne, Kenneth J.
    Moro-Sibilot, Denis
    Camidge, D. R.
    Hirsh, Vera
    Mok, Tony S. K.
    Tassell, Vanessa
    Polli, A.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S445 - S446
  • [42] Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
    Haiyan Xu
    Di Ma
    Guangjian Yang
    Junling Li
    Xuezhi Hao
    Puyuan Xing
    Lu Yang
    Fei Xu
    Yan Wang
    Chinese Journal of Cancer Research, 2019, 31 (02) : 349 - 356
  • [43] Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non-Small-Cell Lung Cancer
    Lin, Yen-Ting
    Wang, Yu-Fen
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    Wu, Shang-Gin
    Shih, Jin-Yuan
    Yang, Pan-Chyr
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) : 1720 - 1725
  • [44] An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer
    Ai, Xinghao
    Shen, Shengping
    Shen, Lan
    Lu, Shun
    BIOCHIMIE, 2015, 112 : 111 - 120
  • [45] Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
    Morcos, Peter N.
    Nueesch, Eveline
    Jaminion, Felix
    Guerini, Elena
    Hsu, Joy C.
    Bordogna, Walter
    Balas, Bogdana
    Mercier, Francois
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 129 - 138
  • [46] Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
    Kilickap, S.
    Ozturk, A.
    Karadurmus, N.
    Korkmaz, T.
    Yumuk, P.
    Cicin, I.
    Paydas, S.
    Cilbir, E.
    Sakalar, T.
    Uysal, M.
    Uskent, N.
    Demir, N.
    Sakin, A.
    Turhal, N.
    Keskin, S.
    Tural, D.
    Eralp, Y.
    Basal, F.
    Yasar, H.
    Sendur, M. A.
    Demirci, U.
    Cubukcu, E.
    Karaagac, M.
    Karaca, S.
    Tatli, A.
    Yetisyigit, T.
    Urvay, S.
    Gursoy, P.
    Uluc, B. Oyan
    Turna, Z.
    Kucukoner, M.
    Olmez, O.
    Cabuk, D.
    Seker, M.
    Unal, O.
    Meydan, N.
    Okutur, S.
    Tunali, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S477 - S478
  • [47] Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Zhang, Yan
    Wang, Yan
    Li, Junling
    Hao, Xuezhi
    Ma, Di
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S377 - S377
  • [48] Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
    Vavala, Tiziana
    Novello, Silvia
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [49] The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer
    Amanam, Idoroenyi
    Gupta, Rohan
    Mambetsariev, Isa
    Salgia, Ravi
    FUTURE ONCOLOGY, 2018, 14 (19) : 1897 - 1908
  • [50] Therapeutic strategies in advanced ALK positive non-small cell lung cancer
    Tiotiu, A.
    Billon, Y.
    Vaillant, P.
    Menard, O.
    Hofman, P.
    Mascaux, C.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (10) : 1107 - 1116
12345